Rekah Pharmaceutical Financials
| REKA Stock | ILA 1,400 8.00 0.57% |
Rekah |
Please note, the presentation of Rekah Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rekah Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Rekah Pharmaceutical's management manipulating its earnings.
Rekah Pharmaceutical Stock Summary
Rekah Pharmaceutical competes with Kamada, Bet Shemesh, Unitronics, PCB Tec, and Ashot Ashkelon. Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.| Foreign Associate | Finland |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0010810096 |
| Business Address | 30 Hamelach Street, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.rekah.co.il |
| Phone | 972 3 558 1233 |
| Currency | ILA |
You should never invest in Rekah Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Rekah Stock, because this is throwing your money away. Analyzing the key information contained in Rekah Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Rekah Pharmaceutical Key Financial Ratios
Rekah Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from Rekah Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of Rekah Pharmaceutical over time and compare it to other companies across industries.| Return On Equity | 0.0222 | |||
| Return On Asset | 0.0208 | |||
| Number Of Employees | 399 | |||
| Beta | 0.0605 | |||
| Z Score | 0.6 |
Rekah Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rekah Pharmaceutical competition to find correlations between indicators driving Rekah Pharmaceutical's intrinsic value. More Info.Rekah Pharmaceutical Industry is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.94 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Rekah Pharmaceutical Industry is roughly 1.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rekah Pharmaceutical Systematic Risk
Rekah Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rekah Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Rekah Pharmaceutical correlated with the market. If Beta is less than 0 Rekah Pharmaceutical generally moves in the opposite direction as compared to the market. If Rekah Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rekah Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rekah Pharmaceutical is generally in the same direction as the market. If Beta > 1 Rekah Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Rekah Pharmaceutical December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rekah Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rekah Pharmaceutical Industry. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on widely used predictive technical indicators. In general, we focus on analyzing Rekah Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rekah Pharmaceutical's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.89 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 16.79 | |||
| Value At Risk | (5.51) | |||
| Potential Upside | 6.89 |
Complementary Tools for Rekah Stock analysis
When running Rekah Pharmaceutical's price analysis, check to measure Rekah Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rekah Pharmaceutical is operating at the current time. Most of Rekah Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Rekah Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rekah Pharmaceutical's price. Additionally, you may evaluate how the addition of Rekah Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |